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Abstract
Background:  Warfarin is commonly used for management of  deep vein thrombosis (DVT) and pulmonary
embolism (PE), controlling therapy by means of  the International Normalized Ratio (INR).
Objectives:  To identify differences in INR results between patients with thromboembolic and haemorrhagic
complications and controls.
Methods: Two nested case-control studies from within a controlled trial of  the duration of  warfarin therapy
(47 thrombotic and16 haemorrhagic complications).
Results: Patients whose thromboembolism failed to resolve during treatment or recurred during or after
treatment had non-significantly lower INR levels than matched controls (geometric mean 2.2 versus 2.3, p =
0.12). Patients with haemorrhage also had not statistically significant lower INR levels than their matched
controls (2.1 versus 2.3, p = 0.22). The variability of  INR levels was similar in both case groups and controls.
The mean percentage of INR levels in the therapeutic range 2  3 was almost identical in thrombotic cases
and controls (56.5% versus 56.1%). Compared to the haemorrhagic group, better control was achieved in
controls (61.5% versus 43.0%, p =0.01), but controls had slightly more INR values above the therapeutic
range (12.1% versus 10.5%, p = 0.74) whilst haemorrhagic cases had more INR values below the therapeutic
range (46.6% versus 26.4%, p = 0.03).
Conclusion: In this study, higher INR levels were not associated with haemorrhage suggesting that, for
patients being treated for DVT/PE, a modest increase in the target therapeutic range could be considered.
Running head:  Warfarin Control in treatment of  DVT/PE
Key words: Deep vein thrombosis; Haemorrhage; International normalized ratio; Pulmonary embolism;
Thromboembolism; Warfarin.
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Introduction
Deep vein thrombosis (DVT) and / or pulmonary
embolism (PE) are the two major manifestations
of venous thromboembolism. The incidence of
DVT in the United Kingdom is one to two people
per 1,000 per year1. Over the past decade, there has
been an extraordinary increase in the use of warfarin
in the UK: about 470,000 patients were estimated
to have received an oral anticoagulant in 2001 with
the figure expected to rise because of the increasing
older population1. In the year 2004, an estimated 2
million N. Americans developed DVT, with more
than 600,000 also experiencing PE2.
Warfarin is the oral anticoagulant prescribed
to this steadily increasing number of patients to
control and prevent thromboembolic disorders.
However, its complex doseresponse relationship
and the narrow therapeutic range, coupled with the
potentially life threatening effects of both under
dosing and overdosing, necessitate close monitoring
of the actual degree of anticoagulation, especially
to balance the risk of excessive bleeding3.
The incidence of bleeding following
warfarin therapy varies from country to country. In
the United Kingdom, the annual rate of fatal bleeds
was reported as 0.6 per 100 patients4.  The overall
incidence of first time idiopathic bleeding was 15.2
per 100 patient-years. The incidence of  fatal and/or
hospitalized and referral was 3.5 and 2.6 per 100
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patient-years respectively4. The annual rate of major
bleeding ranges from 0.9 to 2.7 percent whilst the
median annual rate of fatal bleeding ranges from
0.07 to 0.7 percent in the United States5.
The target levels of warfarin therapy are
disease specific. A target therapeutic INR of 2.0 and
3.0 has long been considered as the safest range for
DVT/PE.  Achieving this range necessitates frequent
monitoring and dose adjustment to prevent fatal
consequences of haemorrhages and recurrent venous
thrombosis/pulmonary embolism from either over
or under anticoagulation.
Based on this narrow therapeutic range,
values below 2.0 and above 3.0 are considered risks
for thrombosis and bleeding respectively6, 7. Wilson
et al.8, in a randomized trial, classified INR values as
High Risk when the values were <1.5 or >5.0
although the justification for this choice was not
stated.
Previous studies have tried to examine the
relationship between different anticoagulant intensity
and complications of bleeding and / or recurrent
thromboembolism1, 9, 10, 11. However, direct
application of the results of these studies is limited
by the populations on which they were conducted,
groups of patients with conditions other than DVT/
PE.
Between September 1999 and December
2002, the Research Committee of the British Thoracic
Society (BTS) conducted a randomized, controlled
trial looking at the outcomes (fatal and non fatal) in
patients with DVT/PE who were treated with
warfarin for either 3 months or 6 months, following
initial  heparin.
The major efficacy outcome variable in the
trial was failure of resolution during treatment and
/ or recurrent thromboembolism during or after
treatment, with major and minor haemorrhages
among these subjects being the main adverse events.
The trial did not show a statistically significant
difference between the two periods of
anticoagulation with respect to the major efficacy
outcome variable, but haemorrhages were more
common in the 6 months group. Although INR
levels were recorded, these were not analyzed in detail
in relation to outcome12.
In view of the above findings, this nested
case-control study, was focused on subjects who
developed the complications of failure of resolution
and / or recurrent thromboembolism or of
haemorrhages, with the aim of identifying differences
in the pattern of INR levels between thrombotic
cases and controls and between haemorrhagic cases
and controls.
Methods
In the BTS trial, 746 patients were randomised to 3
months or 6 months treatment with warfarin,
having met the following inclusion/exclusion criteria:
Inclusion criteria
Aged 18 years or more, suspected or proven DVT
and / or PE, whom the clinician intended to
anticoagulate.
Exclusion criteria
PE deemed so severe by the clinician as to require
thrombolysis or pulmonary          embolectomy.
Neoplasia diagnosed and/or requiring treatment
within the previous three years.
Pregnancy. PE in the preceding three years.
Known polycythaemia, thrombocythaemia,
antithrombin III deficiency. Lupus anticoagulant,
homozygous Factor V Leiden, Protein C or Protein
S deficiency or other similar predisposing
haematological disorders.
Any condition which would result in prolonged or
continuous immobility or confinement to bed e.g.
advanced multiple sclerosis/or orthopaedic
problems of  the lower limbs.
Previous allergy to heparin or warfarin. Requirement
for long-term anticoagulant therapy
Inability to give informed consent, Clinicians were
asked to start warfarin on day one of the scheduled
five days of heparin treatment, usually with low
molecular weight heparin Data for the BTS trial were
collected via standardized clinical research forms
completed prior to randomization and at 3, 6 and
12 months post randomization. The forms contained
questions about demographic characteristics, some
clinical details e.g. diagnosis, investigations, date of
starting warfarin, haemorrhagic or thrombotic
complications, and INR results.
INRs were used to monitor anticoagulation with
warfarin according to a standardised protocol which
was circulated to the participating physicians. The
aim was to achieve INRs between 2 and 3.5.
This case-control study, however, is focused
on warfarin control based on the pattern of the INR
in patients either discovered to have developed
haemorrhage or to have failure of resolution while
on treatment and / or recurrent thromboembolism
during or after treatment, together with matched
controls. It is important to state here that only INR
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measurements before a complication were utilised
in the analysis
In the study design, two, nested, case-control
designs were used. One case-control study involved
those with failure of resolution and / or recurrent
thromboembolism whilst the other involved those
with haemorrhages.
The sample size was determined by the
number of  complications observed in the trial and
power calculations were not relevant.  The adequacy
or limitation of the sample sizes is demonstrated by
the width of  the confidence intervals that are
reported.
Study population and data extraction
To achieve matching of  cases and controls, the study
database was sorted by age, sex, underlying cause
and the randomised duration of warfarin. Cases
were identified and matched to an adjoining control
with the above variables. The INR data of  the cases
and controls were then manually extracted from the
corresponding clinical research forms. Some subjects
were found to have INR data missing. Cases without
INR data were dropped from further consideration,
together with their matched controls. Controls
without INR data were replaced with the next
available subject from the sorted database.
Statistical Analysis
As the INR data were positively skewed, a
logarithmic transformation was used to normalise
the data.
The data were summarised by the use of
descriptive statistics to describe all subjects with
regard to age, sex, diagnosis and the underlying cause
and to obtain confidence intervals where appropriate
for the continuous variables e.g. percentages of  INR
within and out of range and the geometric mean
and the standard deviation of  an individuals INR
values. The continuous variables were compared
between cases and controls using paired t-test or the
non-parametric Wilcoxon signed rank sum test, as
appropriate. All data analysis was carried out using
the Statistical Package for the Social Sciences Version
14 (SPSS v. 14).
Results
A total of 80 cases, along with their paired controls,
was identified, consisting of twenty subjects with
haemorrhages and sixty subjects with failure of
treatment and / or recurrent thromboembolism.
Missing INR data reduced this to 63 cases and 63
matched controls, of whom 16 patients had
haemorrhagic complications and 47 patients had
failed to resolve on treatment or had recurrent
thromboembolism.
The characteristics of the study subjects are
summarized in table 1. The average age of cases
with failure of resolution/recurrent
thromboembolism was 61.2 (SD15.3) years whilst
in cases with haemorrhages the average age was 51.6
(SD 16.8) years. The sex distribution was similar in
both sub-studies, 62% being male.
Table 1: Descriptive characteristics
                    Failure of                            Haemorrhages
                   treatment/recurrent
                    thromboembolism
Case            Control Case      Control
Age
Mean (SD) 61.2 61.2 51.6          51.6
(15.3) (15.3)          (16.8)       (16.9)
Sex:
Male               29 29 10 10
                    (61.7%)         (61.7%)     62.5%)        (62.5%)
Female            18 18   6   6
                    (38.3%)         (38.3%)          (37.5%)   (37.5%)
Diagnosis:
Definitive 41 44 14 16
                  (87.2%)           (93.6%)       (87.5%)           (100)
Probable 6 (12.8%)   3 (6.4%)   2 (12.5%)   -
Underlying cause:
Idiopathic 30 22 9 8
                     (63.8%)     (46.8%)       ((56.3%)       (50.0%)
Immobility   9 10 3 3
                      (19.1%)      (21.3%)     (18.8%)         (18.8%)
Others   8 15 4 5
(17.0%)        (31.8)       (25.1%)         (31.3%)
Length of treatment
3 months 27 28   5   5
                  (57.4%)           (59.6%)         (31.3%)    (31.3%)
6 months 20 19 11 11
                 (42.6%)            (40.4%)         (68.7%)    (68.7%)
The geometric mean INR of subjects with failure
of resolution and/or recurrent thromboembolism
was 2.20 (95% C L, 2.10 to 2.29), vs. 2.30 (95% CL,
2.18 to 2.43) in the controls; ratio 0.96, 95% C.L
0.90 to 1.01, P = 0.12.
In the subjects with haemorrhagic
complications, the geometric mean INR was 2.14
(95% CL, 1.95 to 2.36), vs. 2.31 (95% CL, 2.12 to
2.52) in the controls; ratio 0.93, 95% C.L 0.82 to
1.05, P = 0.22. For both haemorrhage and
recurrences, the ratio of the geometric means of
cases and controls was therefore not statistically
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significant.
Percentage in therapeutic range
In the analysis comparing the level of warfarin
control in terms of  the percentage of  INRs within
the usual therapeutic range of 2-3 in subjects with
failure of resolution and / or recurrent
thromboembolism, there was no statistically
significant difference between cases and controls:  the
mean percent in range in cases was 56.5% (95% C.L.
50.3% to 62.8%), vs. 56.1% (95% C.L. 49.7% to
62.6%) in the controls; (P = 0.93).
Similarly, the percentage of  INRs above the
therapeutic range was 12.8% (95% C.L. 8.8% to
16.9%) in cases, vs. 16.8% (95% C.L. 12.1% to
21.6%) in the controls; (P = 0.09).
However, the percentage of INRs within range
differs between cases with haemorrhage and their
control group: the mean percent within range among
cases was 43.0% (95% C.L. 33.3% to 52.7%), vs.
61.5% (95% C.L. 52.8% to 70.2%) in the controls;
(P = 0.01).  There was no significant difference
between the two groups in the analysis of mean
percentages of INR values above the range; cases
10.5% (95% C.L.3.6 to 17.3), vs. 12.1% (95% C.L.
4.8 to 19.4) in the controls; (P = 0.74).
Correspondingly an excess of those with INR levels
below the therapeutic range was seen in patients with
haemorrhages (46.6% [95% C.L. 33.8% to 59.4%]
compared to controls (26.4% [95% C.L. 17.7% to
35.3%]; P = 0.03).
Pattern of  standard deviation among cases and
controls
The difference in the mean standard deviation of
log INR values among the subjects with failure of
resolution/recurrent thromboembolism and controls
was not statistically significant (0.12 [95% C.L. 0.10
to 0.14] vs. 0.13 [95% C.L. 0.12 to 0.15]; P = 0.25)
as shown in Figure 1 below.
Figure 1: Illustrating the relationship between
the standard deviation of the log of INR of
clotters and controls
The difference in the mean standard deviation
of log INR values among the haemorrhagic subjects
and controls was also not statistically significant (0.12
[95% C.L. 0.09 to 0.14] vs. 0.12 [95% C.L. 0.09 to
0.15]; P = 0.95) as shown in Figure 2.
Figure 2: Graph illustrating the relationship
between the standard deviation of the log of
INR of bleeders and controls
Maximum INR values among subjects with
haemorrhages and paired controls
The maximum INRs were similar in both groups as
shown in Figure 3.  However, more of the control
subjects (12.5%) had INR values > 4.5 compared
to the haemorrhagic group (6.3%), although this
difference between the two groups was not
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statistically significant by the Wilcoxon signed rank
sum test (P = 0.45).
Discussion
International Normalized Ratio has long been used
to control the intensity of warfarin therapy for
various thromboembolic conditions including DVT
and / or PE. Traditionally, INR values in the range
of 2.0-3.0 are considered as the optimum therapeutic
range for the prevention of haemorrhage, failure
of resolution and recurrent thromboembolism
during oral anticoagulation management of DVT
and / or PE.  According to Wilson et al.8, INR values
consistently below 1.5 are a risk factor for the re-
occurrence of thromboembolism whilst INR values
above 5.0 are a risk for haemorrhages7. In support
of this report is the earlier finding by Berwaerts et
al.11, of the danger associated with values of INR
above 4.5, especially in terms of  haemorrhagic
complications, although they emphasised the fact that
sub-therapeutic INR values cannot be considered
to be entirely safe in protecting against intracranial
haemorrhages.
In this study, High Risk INRs were not
generally observed either among cases with failure
of resolution and / or recurrent thromboembolism
or haemorrhagic complications. Unequivocally most
of the subjects in this study had INR values within
the standard therapeutic range of 2.0-3.0. The
geometric means of subjects with failure of
resolution / recurrent thromboembolism was 2.2
vs. 2.3 in the controls and 2.1 vs. 2.3 for those with
haemorrhages and controls respectively. The
geometric means for cases did not differ significantly
from the control groups although the values in both
sets of  controls were higher than in the cases.
Haemorrhagic complications occurring within the
therapeutic range are not uncommon, especially
among patients with other co-morbidities e.g.
gastrointestinal lesions, urinary tract infections,
thrombocytopaenias, anaemia, renal insufficiency etc.
This fact, combined with the finding of higher INR
values among the controls, suggests that higher INRs
were unlikely to have been responsible for the
occurrence of  haemorrhages in this study.
A similar case-control study conducted by
Fang et al.9, found that most cases (62%) of
intracranial haemorrhages among patients with atrial
fibrillation occurred at INR below 3.0 although the
results did support the finding of previous studies
that an increase of intracranial haemorrhages was
associated with higher INR values. In the current
study, only one case of  subarachnoid haemorrhage
was found among the DVT and/or PE subjects.
Other types of haemorrhages ranged from
menorrhagia to gastrointestinal bleeding.
In terms of  the level of  warfarin control,
the mean percentage of INRs within range was not
different between thrombotic patients and controls:
56.5% vs. 56.1% (P = 0.93). This finding is different
from the expected one of better anticoagulation
among the controls as opposed to those with
thrombotic complications.
However, expected results were seen among
the haemorrhagic group and paired controls in the
sense that warfarin control was relatively better in
the control group when compared to the
haemorrhagic cases, (61.5% vs. 43.0%),this difference
between the two groups being statistically significant
(P = 0.01).  If there were to be an increased bleeding
risk at higher INR levels, one would expect more
of  the observations from cases to be above the
therapeutic range but the reverse was observed. The
percentage value above the range was higher in the
controls (12.1%) than those with haemorrhagic
complications (10.5%), leaving an excess of INR
readings below the therapeutic range in those with
haemorrhage.
Further to this, the results of the maximal
INR values among haemorrhagic cases and controls
were similar although, again more of the control
subjects had INR values above 4.5. It is important
to note here that in one particular subject among the
control group, INR values ranging from 4.6 to 10.8
were recorded. In terms of  the standard deviation
of the INR values, there was no statistically significant
difference between cases and controls.
The overall results in this study raise the
Figure 3: Graph illustrating maximum INR among
cases with bleeding complication with the paired
controls
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possibility that it may be possible to raise the target
range for INR without an excessive risk of
accompanying haemorrhage. However, this finding
is in contrast to the report of  an observational study
of  Barclay and Vega et al 10, who found that the risk
of major bleeding decreased from 3.6 per 100
patient-years in patients with high intensity warfarin
treatment to 2.7 per 100 patient-years in patients with
low intensity warfarin treatment. This observation,
however, was made among patients with atrial
fibrillation who are more at risk of bleeding
complications than those with DVT and / or PE.
This study is limited by a number of factors:
the small sample size, especially among the
haemorrhagic groups of  subjects. A total number
of eighty cases along with their paired controls were
identified and they consisted of twenty subjects with
haemorrhages and sixty subjects with failure of
treatment and / or recurrent thromboembolism.
During subsequent compilation, some cases and
controls were discovered to have missing INR values.
Cases with missing INR values were dropped from
the analysis, while controls with missing INR values
were replaced with the next matched. At the end of
the above processes, the initial sample number of
eighty cases and paired controls had reduced to sixty
three cases / paired controls.
The small sample size makes it difficult to
make a firm conclusion from the findings in this
study. We note though that the 95% confidence limits
for the ratio of mean INRs in haemorrhagic cases
and controls rules out INR levels being more than
5% higher in those with haemorrhage.  Also, lack of
information regarding the dose of  warfarin,
administered concomitant drugs and co-morbid
conditions, limits the possibility of allowing for
confounders.
However, this study was on information
collected by the Research Committee of the BTS in
their prospective, randomized trial in which data were
recorded in a standard way at set intervals.  Such
information can be adjudged to be of  good quality.
The inclusion / exclusion criteria in the BTS
study allowed the recruitment of a broad range of
patients drawn from all over the UK and managed
within the National Health Service.  The exclusion
criteria were confined to those for whom treatment
for 3 or 6 months with warfarin was unlikely to be
efficacious or safe. The findings of this study will
therefore apply to a substantial proportion of patients
presenting with DVT and/or PE. Care has to be
taken not to extrapolate these findings to the
categories of patients who have been excluded, with
those with recent neoplasia being the most important
such group.
We note that the geometric means in this
study were in the lower part of the therapeutic range
of 2.0-3.0 even though the BTS therapeutic guideline
in the trial was 2.0 to 3.5. Therefore the findings
support the idea of raising the upper limit of the
present narrow therapeutic range of 2.0-3.0 to at
least 3.5, if  not higher. A corresponding rise in the
lower limit to 2.5 might also be considered so that
levels of anticoagulation that may be more effective
in treating and preventing the recurrence of
thromboembolism are achieved in practice.
Conclusion
The pattern of INR values examined among DVT
and / or PE subjects with complications of failure
of resolution/recurrent thromboembolism and
haemorrhages, revealed that the overall geometric
means, as well as the percentage of INR above the
range, were higher among the control groups
compared to the cases. This suggests that raising the
upper limit of the therapeutic range of 3.0 to 3.5, as
in the BTS study and also raising the lower limit to
2.5 might possibly be an option for the treatment
of DVT/PE, which would not incur an excessive
risk of  accompanying haemorrhage. This suggestion
thus allows for a more liberal but yet concise use of
warfarin therapy.
Close monitoring remains essential for those
subjects with co-existing morbidities, who are the
group most likely to bleed at any therapeutic INR
range.
Further randomized control trials are needed to
refine the optimal therapeutic range for INR level in
the treatment of venous thromboembolism.
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